

Publication

**EP 0668770 A4 19950927**

Application

**EP 92911434 A 19920415**

Priority

- US 9203119 W 19920415
- US 69075591 A 19910424
- US 85208692 A 19920320

Abstract (en)

[origin: WO9219254A1] The compounds of the invention are alpha -substituted mono-, di-, tri-, tetra-, and pentapeptides useful in treating obesity, anxiety, gastrointestinal ulcers, pain, stroke, and inflammation. They are also useful in blocking the reaction caused by withdrawal from drug or alcohol use and in reducing gastric acid secretion. They are further useful as agents in hypertension, heart failure, stroke, cognition, memory enhancement, spasticity, depression, diabetes, cancer, asthma, bladder dysfunction, psychosis, and arthritis and/or inflammatory pain. Pharmaceutical compositions, novel intermediates, and processes are also included.

IPC 1-7

**A61K 38/00**

IPC 8 full level

**A61K 38/00** (2006.01); **A61K 38/22** (2006.01); **A61P 1/04** (2006.01); **A61P 3/04** (2006.01); **A61P 9/00** (2006.01); **A61P 9/12** (2006.01); **A61P 11/00** (2006.01); **A61P 13/02** (2006.01); **A61P 15/00** (2006.01); **A61P 25/00** (2006.01); **A61P 25/04** (2006.01); **A61P 25/20** (2006.01); **A61P 25/24** (2006.01); **A61P 25/26** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 5/06** (2006.01); **C07K 5/065** (2006.01); **C07K 5/078** (2006.01); **C07K 5/08** (2006.01); **C07K 5/09** (2006.01); **C07K 5/097** (2006.01); **C07K 5/10** (2006.01); **C07K 5/107** (2006.01); **C07K 5/113** (2006.01); **C07K 7/06** (2006.01); **C07K 14/66** (2006.01); **C07K 14/70** (2006.01)

CPC (source: EP)

**A61P 1/04** (2017.12); **A61P 3/04** (2017.12); **A61P 9/00** (2017.12); **A61P 9/12** (2017.12); **A61P 11/00** (2017.12); **A61P 13/02** (2017.12); **A61P 15/00** (2017.12); **A61P 25/00** (2017.12); **A61P 25/04** (2017.12); **A61P 25/20** (2017.12); **A61P 25/24** (2017.12); **A61P 25/26** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07K 5/06043** (2013.01); **C07K 5/06078** (2013.01); **C07K 5/06156** (2013.01); **C07K 5/0815** (2013.01); **C07K 5/0821** (2013.01); **C07K 5/0825** (2013.01); **C07K 5/1016** (2013.01); **C07K 5/1021** (2013.01); **C07K 7/06** (2013.01); **C07K 14/66** (2013.01); **C07K 14/70** (2013.01); **A61K 38/00** (2013.01)

Citation (search report)

- [A] EP 0405537 A1 19910102 - WARNER LAMBERT CO [US]
- [A] EP 0146266 A2 19850626 - ORTHO PHARMA CORP [US]
- [A] EP 0342962 A2 19891123 - IMMUNOBIOLOGY RES INST INC [US]
- [A] EP 0007615 A2 19800206 - MERCK & CO INC [US]
- [A] D.ROSSI ET AL.: "Hydrolysis of N-phenylacetyl-alpha-amino acids by benzylpenicillinacylase", EXPERIENTIA, vol. 41, no. 1, 1985, BASEL, pages 35 - 37
- [A] H.BRÜCKNER ET AL.: "Determination of Non-Protein alpha-Alkyl-apha-Amino Acids by Reserved-Phase High-Performance Liquid Chromatography in Comparison With Ion-Exchange And Capillary Gas Chromatography", J.CHROMATOGEPHY, vol. 386, 1987, pages 251 - 272
- [A] G.A.HEAVNER ET AL.: "Biologically Active Analogs of Thermopentin with Enhanced Enzymatic Stability", PEPTIDES, vol. 7, 1986, USA, pages 1015 - 1019
- See references of WO 9219254A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

DOCDB simple family (publication)

**WO 9219254 A1 19921112**; AU 1907292 A 19921221; CA 2106764 A1 19921025; EP 0668770 A1 19950830; EP 0668770 A4 19950927; IE 921321 A1 19921104; JP H06507402 A 19940825; NZ 242441 A 19950224; PT 100422 A 19930930

DOCDB simple family (application)

**US 9203119 W 19920415**; AU 1907292 A 19920415; CA 2106764 A 19920415; EP 92911434 A 19920415; IE 921321 A 19920423; JP 51140192 A 19920415; NZ 24244192 A 19920422; PT 10042292 A 19920423